Core Insights - MDB Capital Holdings, LLC plans to host a Zoom webinar on May 21, 2025, to discuss its first quarter 2025 results [1][2] - The webinar will be led by CEO Christopher Marlett and will include discussions on recent developments, ongoing initiatives, and anticipated milestones [2] Company Overview - MDB Capital Holdings, founded in 1997, focuses on transforming deep technology ideas into valuable public companies through a unique public venture capital approach [3] - The company specializes in community-driven financings of pre-revenue, early-stage deep technology companies, primarily through initial public offerings (IPOs) on NASDAQ [3] Services Offered - MDB Capital operates as a self-clearing broker-dealer and provides services through its MDB Direct trading platform and PatentVest, an integrated intellectual property intelligence and consulting firm [4] - MDB Capital is a registered broker-dealer and a member of FINRA and SIPC [4]

[PART I - FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) This section provides the unaudited condensed consolidated financial statements and management's discussion and analysis for the period ended March 31, 2025 [Item 1. Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section presents MDB Capital Holdings, LLC's unaudited interim financial statements, including balance sheets, statements of operations, equity changes, cash flows, and explanatory notes for Q1 2025 and 2024 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets were **$68.6 million**, a decrease from **$72.0 million** at December 31, 2024, primarily due to a reduction in cash and cash equivalents and the fair value of investment securities Condensed Consolidated Balance Sheet Summary (Unaudited) | Account | March 31, 2025 (USD) | December 31, 2024 (USD) | | :--- | :--- | :--- | | **Total Assets** | **$68,626,418** | **$71,976,399** | | Cash and cash equivalents | $19,551,997 | $20,437,492 | | Investment securities, at fair value | $5,385,918 | $5,858,336 | | Equity method investment | $40,891,050 | $41,763,568 | | **Total Liabilities** | **$1,640,020** | **$1,903,065** | | **Total Equity** | **$66,986,398** | **$70,073,334** | [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2025, the company reported a net loss of **$6.6 million**, an improvement from a net loss of **$7.6 million** in the same period of 2024, driven by new fee income of **$2.1 million** and lower operating costs Consolidated Statements of Operations Summary (Unaudited) | Metric | Three Months Ended March 31, 2025 (USD) | Three Months Ended March 31, 2024 (USD) | | :--- | :--- | :--- | | Total operating income (loss), net | $828,098 | $(660,389) | | Fee income | $2,140,238 | $0 | | Total operating costs | $6,738,002 | $7,286,791 | | Net operating loss | $(5,909,904) | $(7,947,180) | | Net loss | $(6,601,793) | $(7,609,328) | | Net loss attributable to MDB | $(6,587,362) | $(7,215,425) | | Loss per Class A share – basic and diluted | $(0.66) | $(0.78) | [Unaudited Condensed Consolidated Statements of Changes in Equity](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Equity) Total equity decreased from **$70.1 million** at the end of 2024 to **$67.0 million** as of March 31, 2025, primarily due to a net loss of **$6.6 million**, partially offset by **$3.5 million** in stock-based compensation Changes in Equity for Three Months Ended March 31, 2025 (Unaudited) | Description | Amount (USD) | | :--- | :--- | | Balance, December 31, 2024 | $70,073,334 | | Stock-based compensation | $3,514,857 | | Net loss | $(6,601,793) | | **Balance, March 31, 2025** | **$66,986,398** | [Unaudited Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the three months ended March 31, 2025, net cash used in operating activities was **$1.3 million**, compared to **$2.3 million** in the prior-year period, resulting in a net decrease in cash of **$1.3 million** with the period-end balance at **$20.0 million** Consolidated Statements of Cash Flows Summary (Unaudited) | Cash Flow Category | Three Months Ended March 31, 2025 (USD) | Three Months Ended March 31, 2024 (USD) | | :--- | :--- | :--- | | Net cash used in operating activities | $(1,257,855) | $(2,259,097) | | Net cash provided by investing activities | $0 | $3,445,523 | | Net cash used in financing activities | $0 | $(91,507) | | **Net (decrease) increase in cash** | **$(1,257,855)** | **$1,094,919** | | **Cash at end of period** | **$20,023,378** | **$8,452,606** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail MDB's corporate structure, significant accounting policies, and financial activities, including subsidiary operations, the deconsolidation of eXoZymes, segment performance, equity structure, and subsequent events - MDB operates as a holding company with subsidiaries including Public Ventures (broker-dealer), PatentVest (IP services), and M1 (pharmaceutical development), with eXoZymes deconsolidated in November 2024 to an equity method investment[21](index=21&type=chunk)[25](index=25&type=chunk)[102](index=102&type=chunk) - The company operates in two segments: Broker Dealer & Intellectual Property Service, and Technology Development, with the Broker Dealer segment generating **$0.83 million** in net operating income and the Technology Development segment incurring a **$44.8 thousand** net operating loss in Q1 2025[84](index=84&type=chunk)[85](index=85&type=chunk)[88](index=88&type=chunk) - As of March 31, 2025, **4,950,632 Class A shares** and **5,000,000 Class B shares** were outstanding, with Class B shares carrying five votes per share and being convertible to Class A shares on a one-to-one basis[96](index=96&type=chunk)[97](index=97&type=chunk) - Public Ventures, the company's broker-dealer subsidiary, maintained **$10.2 million** in net capital at March 31, 2025, exceeding the minimum requirement by **$9.9 million**[117](index=117&type=chunk) - Subsequent to quarter-end, on April 28, 2025, key executives voluntarily exchanged outstanding RSUs for stock options equivalent to Class A shares[135](index=135&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=33&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the Q1 2025 financial results, noting a reduced net loss driven by new fee income and lower operating costs, improved segment performance, and strong liquidity despite a decrease in working capital Consolidated Results of Operations Comparison (Unaudited) | Metric | Three Months Ended March 31, 2025 (USD) | Three Months Ended March 31, 2024 (USD) | | :--- | :--- | :--- | | Total operating income (loss), net | $828,098 | $(660,389) | | Total operating costs | $6,738,002 | $7,286,791 | | Net loss | $(6,601,793) | $(7,609,328) | | Net loss attributable to MDB | $(6,587,362) | $(7,215,425) | - The Broker Dealer & IP Service segment's net loss decreased to **$1.44 million** in Q1 2025 from **$2.19 million** in Q1 2024, primarily due to **$2.14 million** in new investment banking fee income[148](index=148&type=chunk)[150](index=150&type=chunk) - The Technology Development segment's net loss attributable to controlling interests decreased to **$30.4 thousand** in Q1 2025 from **$614.6 thousand** in Q1 2024, mainly due to the deconsolidation of eXoZymes[152](index=152&type=chunk) - Working capital decreased to **$20.2 million** at March 31, 2025, from **$27.3 million** a year prior, primarily due to cash used in operations[162](index=162&type=chunk) - Critical accounting estimates include revenue recognition for investment banking, potentially involving warrants valued with the Black-Scholes model, and fair value measurement of financial instruments across Level 1, 2, and 3 hierarchies[169](index=169&type=chunk)[170](index=170&type=chunk)[171](index=171&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is a smaller reporting company and is therefore not required to provide the information requested under this item - As a smaller reporting company, MDB is not required to provide quantitative and qualitative disclosures regarding market risk[187](index=187&type=chunk) [Item 4. Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of March 31, 2025, due to a material weakness in internal control over financial reporting, though financial statements are fairly presented and remediation efforts are underway - The CEO and CFO concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to a material weakness in internal control over financial reporting[188](index=188&type=chunk) - Despite the material weakness, management performed additional analyses and concluded that the financial statements in the 10-Q are fairly stated in all material respects[188](index=188&type=chunk) - The company is implementing measures to remediate the material weakness, including redesigning the financial reporting process, with remediation confirmed only after new controls operate effectively for a sufficient period[189](index=189&type=chunk)[190](index=190&type=chunk) [PART II - OTHER INFORMATION](index=44&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) This section covers other information including legal proceedings, risk factors, unregistered sales of equity, defaults, mine safety disclosures, and exhibits [Item 1. Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) As of the filing date, the company is not a party to any material legal proceedings and is not aware of any pending or threatened litigation that would have a material adverse effect on its business or financial condition - The company is not currently a party to any material legal proceedings[194](index=194&type=chunk) [Item 1A. Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) This section highlights key risks, including the potential adverse effects of changes in U.S. tariff, import/export regulations, and trade policies on the global economy and the company's financial services business - Changes to U.S. tariff and trade policies could materially adversely affect global economic conditions and the company's business, financial condition, and results of operations[196](index=196&type=chunk) - Government actions, including changes in tariffs and reductions in research funding, may impede the company's ability to conduct research and raise capital for its partner companies and clients[197](index=197&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - No unregistered sales of equity securities occurred during the period[198](index=198&type=chunk) [Item 3. Defaults upon Senior Securities](index=44&type=section&id=Item%203.%20Defaults%20upon%20Senior%20Securities) The company reported no defaults upon senior securities - No defaults upon senior securities were reported[199](index=199&type=chunk) [Item 4. Mine Safety Disclosures](index=44&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - This item is not applicable to the company[200](index=200&type=chunk) [Item 5. Other Information](index=44&type=section&id=Item%205.%20Other%20Information) This item is not applicable to the company - This item is not applicable to the company[201](index=201&type=chunk) [Item 6. Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including certifications from the CEO and CFO, and Inline XBRL data files - This section lists the exhibits filed with the Form 10-Q, including officer certifications and XBRL files[202](index=202&type=chunk)[207](index=207&type=chunk)

Company Overview and Strategy - MDB Capital aims to transform deep technology "Big Ideas" into valuable public companies[6] - The company's goal is to enable investors to create a portfolio of 10–12 MDB curated venture-stage companies over time[7] - MDB's platform helps stand up and launch deep tech new category leaders[10] Pipeline and Due Diligence - In 2024, MDB screened 8,964 private and public companies and further examined 219 to identify deep tech ideas[21] - The number of private companies reviewed increased by 107% from 3,391 in 2023 to 7,025 in 2024[22] - The number of public companies under surveillance increased by 35% from 1,432 in 2023 to 1,939 in 2024[22] - Companies further examined increased by 366% from 47 in 2023 to 219 in 2024[22] Financial Performance and Investments - MDB's direct assets increased significantly by 2,092% from $2,016,959 in 2023 to $44,215,968 in 2024[22] - The company completed an IPO for Invizyne Technologies (now eXoZymes Inc (EXOZ)) in November 2024, raising $15 million[21,40] - MDB's initial investment of $5.9 million in eXoZymes translated into a $150 million market cap company[40] - MDB owns 47% of eXoZymes' outstanding stock[40] Market Positioning and Future Outlook - MDB is well-positioned for 2025 due to a significant increase in micro-cap deal opportunities and a growing demand for micro-cap financing[29,34] - Venture Capital fundraising declined by nearly 58% in 2023 and by 23-25% in 2024[31]

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, and Big Idea investments, represented by eXoZymes, was $64 million, totaling approximately $93 million [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by the end of the year [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority is to expand the investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to transition from episodic deal-making to creating a consistent public venture asset class portfolio [34] - The company is optimistic about presenting new Big Idea investment opportunities in the near future, with a focus on companies that are more developed and potentially have revenue [80] Management's Comments on Operating Environment and Future Outlook - Management is excited about the significant increase in opportunities being presented, both from community members and through their own curation efforts [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies and reducing cash operational expenses while increasing revenue from various lines [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing that opportunity, with plans for potential further investment [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas this year, with some being more developed and potentially having revenue [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to see a value-creating event within eXoZymes before considering any distributions to shareholders [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, with Big Idea investments represented by eXoZymes valued at $64 million, totaling approximately $93 million in cash and securities [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by year-end [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority for the company is to expand its investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to present one to two new Big Idea investment opportunities in the next quarter, indicating a robust pipeline of potential investments [52][53] - The company is evolving from a model of episodic deal-making to creating a consistent public venture asset class portfolio [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the increasing number of opportunities being presented, both from community members and through proactive curation [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies while managing cash expenditures, with hopes of reducing operational costs over the next 12 months [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing this opportunity, although no specific updates were provided [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier for investors to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas in 2025, with some companies already in advanced discussions for potential IPOs [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is expected to improve, facilitating new offerings, although there are uncertainties regarding FDA timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to wait for a solid footing under eXoZymes before considering any distributions to avoid disrupting the market [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]

Core Insights - The PatentVest Pulse report highlights the significance of intellectual property (IP) control in shaping the future of brain-computer interfaces (BCIs) and neurotechnology [1][4] - Neurological disorders are a rapidly growing area in global healthcare, with BCIs emerging as a next-generation solution to address these challenges [2][3] Market Overview - The U.S. BCI market is projected to exceed $400 billion, with $80 billion focused on high-acuity patient populations and $320 billion in long-term potential across broader neurological and psychiatric conditions [3] - Early alignment of IP, clinical validation, and commercialization strategies will be crucial for companies to scale in this vast market [3] Competitive Landscape - The report provides a comprehensive analysis of the BCI market, profiling key players such as Synchron, Neuralink, Blackrock Neurotech, and others, while mapping over 2,160 patent families across 664 entities [4][9] - Companies like Synchron and INBRAIN are establishing leadership through innovative strategies, while Neuralink garners significant media attention [6][9] Intellectual Property Dynamics - More than 2,160 unique BCI patent families are held by various companies, indicating an accelerating competition for control over system-level IP [9] - Academic institutions, including Tianjin University and Stanford, continue to dominate early-stage innovation, holding foundational patents that support commercial efforts in the BCI space [9]

Investment Strategy - MDB Capital Holdings operates as a foundational platform for financing startups, focusing on community-driven micro and small-cap financings ranging from $5 million to $60 million[23]. - MDB's investment strategy includes a two-step financing approach, providing initial seed capital of $5 million to $10 million, followed by additional funding of $20 million to $60 million for commercialization[31]. - MDB aims to take a majority ownership stake in partner companies, planning to seek one or two partner company opportunities per year[54]. - MDB intends to maintain at least 35% voting stock in partner companies, ensuring influence over management and strategic direction[55]. - MDB's investment philosophy focuses on identifying early-stage companies with disruptive technologies that can sustain value in public markets[29]. Partner Companies and Development - The Big Idea Pipeline identifies approximately 250 technologies annually, narrowing down to about 50 active Big Idea Companies, with two currently in active negotiations for potential partnership or investment[26]. - MDB's partner companies must demonstrate "Tech Leadership Potential," "Platform Technology," and "Large Market Potential," ensuring a robust intellectual property position[27]. - Three companies founded by MDB, Provention Bio, Cue BioPharma, and Pulse Biosciences, have traded at or above $1 billion in market value, enhancing their ability to raise capital for commercialization[34]. - MDB's model emphasizes long-term involvement with partner companies, including board membership and strategic business advice post-IPO[32]. - The company aims to create a strong foundation for partner companies during their development phase to attract top talent and ensure long-term success[39]. Community and Investor Relations - MDB's community consists of over 500 sophisticated investors who support the public venture model and advocate for the partner companies[45]. - MDB shareholders can buy or sell shares in the holding company at any time, participating in capital formation through private placements or public offerings[52]. - The company expects to provide substantial capital to partner companies more easily than traditional venture capital, enhancing growth potential[51]. - MDB's public venture model is designed to offer liquidity, efficiency, and transparency, addressing the unique needs of early-stage companies[49]. Intellectual Property and Technology Commercialization - PatentVest is expanding operations to optimize technology commercialization, transforming complex legal processes into manageable business processes[75]. - The company plans to leverage its proprietary patent database to enhance the value of inventions and guide strategic business decisions[76]. - PatentVest has built a proprietary patent database containing over 148 million patents across 116 countries, enhancing its ability to support technology companies[86]. - The PatentVest process is expected to guide technology companies in prioritizing ideas and developing intellectual property strategies, enhancing their market position[85]. - PatentVest's legal services will focus on intellectual property matters, enhancing the value of inventions through strategic legal support[88]. Regulatory and Compliance Risks - The company’s broker-dealer, Public Ventures, must comply with SEC Regulation S-P, which mandates policies for protecting client information and providing privacy notices[112]. - The company faces risks from potential security breaches, which could lead to significant legal and financial exposure, as well as reputational damage[114]. - The company is subject to stringent privacy and data protection laws, including the Gramm-Leach-Bliley Act and the California Consumer Privacy Act, which could result in liabilities and require modifications to data handling practices[183][184]. - The California Privacy Rights Act, effective January 1, 2023, imposes additional obligations on the company regarding data privacy and may increase compliance costs[184]. - The company anticipates that more states will enact privacy legislation similar to the CCPA, which could complicate compliance and increase legal risks[186]. Operational Structure and Growth - The company currently employs approximately 16 full-time employees and engages consultants for various activities, indicating a lean operational structure[127]. - The company anticipates growth in the number of employees and consultants as operations expand[129]. - The company has funded operations primarily through equity financings and revenue generated by services since inception in 2022[143]. - The company may require additional capital to support operations and business growth, which might not be available when needed[143]. - The business model does not rely on operating cash flows from partner companies, which are expected to not generate revenues or positive cash flow during development[147]. Market and Competitive Landscape - MDB faces competition from other capital providers in acquiring and developing partner companies, which may lead to higher acquisition costs and increased risk of loss[177]. - The company recognizes competition from traditional venture capital firms and aims to differentiate through community support and development of partner companies[60]. - Political and regulatory environments in the U.S. and Nicaragua pose risks that could adversely affect MDB's operations and financial condition[164]. - The company believes that the conflicts involving Ukraine and Israel do not have a direct impact on its operations or financial condition, but may have general effects due to international sanctions and inflation[182]. Challenges and Risks for Partner Companies - The company’s partner companies may encounter challenges typical of early-stage companies, including regulatory and market penetration issues[148]. - The company’s management will need to effectively manage growth and expansion of partner companies, which imposes significant responsibilities[149]. - Partner companies may face challenges in protecting their proprietary rights and could infringe on the rights of others, leading to potential litigation[200]. - Limited foreign intellectual property rights may hinder the ability to protect intellectual property globally, impacting competitive position[204]. - Collaborations with third parties are essential for research and development, and failure to maintain these arrangements could adversely affect business[212]. M1 Company Specifics - M1, a partner company, aims to develop a small molecule anti-senescence platform targeting age-related diseases, with the global market projected to reach nearly $45 billion by 2030[91]. - M1 entered into a License Agreement with Mayo, granting exclusive rights to develop and commercialize patented technology, issuing 1,980,000 shares representing 33% of its shares and paying an initial license fee of $150,000[92][93]. - M1 is currently in the pre-clinical development stage, conducting feasibility studies and collecting drug safety data, with milestone payments required for clinical trial initiations[95][96]. - M1's compounds are novel, necessitating extensive safety and efficacy testing to gain market acceptance and regulatory approval[220]. - The success of M1 is highly dependent on hiring and retaining specialized scientific staff, which may be challenging due to high demand for such talent[221].

Core Insights - MDB Capital Holdings, LLC is focused on launching deep technology companies and has made significant progress in a challenging venture market, highlighting the value of its public venture approach [2][6] Operational Highlights - The company successfully completed its first full year of its clearing and trading platform and has expanded its investor community by 12%, onboarding 456 new brokerage accounts and increasing assets under management from approximately $2 million to $44 million [6] - MDB Capital launched an initial public offering for eXoZymes Inc, a company spun out from UCLA, and currently owns about 47% of its outstanding shares [6] - The firm increased its analyst team to 14, screening 8,964 companies and examining 217 for potential market leadership, resulting in a strong pipeline of "Big Ideas" [6] - MDB Capital operates a self-clearing broker-dealer and an online investment platform specifically for public venture investing, enhancing its service offerings [6][8] Financial Reporting - The company filed its Form 10-K with the SEC, which includes consolidated financial results for all operations, including eXoZymes' performance until its IPO on November 14, 2024 [6]

Core Viewpoint - MDB Capital Holdings, LLC plans to host a Zoom webinar on March 31, 2025, to discuss its fourth quarter and full year 2024 results, with a press release to be issued prior to the call [1][2]. Company Overview - MDB Capital Holdings, LLC, founded in 1997, focuses on transforming deep technology ideas into valuable public companies through a unique public venture capital approach, primarily targeting pre-revenue, early-stage companies [3]. - The company operates under the MDB Capital brand, which includes a self-clearing broker-dealer and the PatentVest firm, specializing in intellectual property intelligence and consulting [4].

Core Insights - PatentVest released the "AI-Driven Data Centers – The Patent Race Reshaping AI Infrastructure" report, analyzing the evolving AI data center market and its implications for future infrastructure [1] - The enterprise data generation is expected to reach 1.2 million exabytes by 2025, necessitating advancements in digital infrastructure to support AI workloads [2] - The data center as a service market, valued at $71.92 billion in 2022, is projected to grow to $431.43 billion by 2030, driven by demand for AI-optimized infrastructure [3] Market Dynamics - AI-driven data centers are integrating AI-specific semiconductors, high-speed interconnects, liquid cooling, and renewable energy solutions to enhance efficiency and sustainability [3] - Intellectual property (IP) is crucial for unlocking the potential of evolving data centers, with companies expanding patent portfolios to secure foundational technologies [6] - The report highlights the competitive patent landscape, identifying key players and gaps in patent coverage that present opportunities for innovation [6] Competitive Landscape - The AI data center market is witnessing a surge in patent filings, with 77% of all filings originating from China, indicating its dominant role in shaping AI infrastructure [8] - Leading innovators include five top patent holders from China, one from South Korea, and others from the United States, showcasing a diverse competitive environment [8] - Patent disputes, such as Intel's $2.18 billion ruling and Netlist's $118 million lawsuit against Samsung, emphasize the strategic importance of IP in the sector [8]